SGLT2 inhibitor to prevent diabetes after kidney transplant
Part of Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests whether a medication called an SGLT2 inhibitor can help prevent new-onset diabetes after a kidney transplant. It is for people who have received a kidney transplant, do not have diabetes, and are taking tacrolimus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received a kidney transplant and do not have diabetes.
- You are at least 18 years old.
- Your anti-rejection medicines must include tacrolimus.
- Your kidney function (eGFR) needs to be 25 mL/min/1.73 m² or higher.
- You cannot have certain chronic intestinal diseases such as Crohn's disease, ulcerative colitis, or short bowel syndrome.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called SGLT2i (a type of pill for kidney health) is safe and helpful for kidney transplant recipients who do not have diabetes. It aims to see if it can improve how the new kidney works.
This trial tests if the drug semaglutide can prevent the development of diabetes in people who have recently had a kidney transplant. It may help those at higher risk for post-transplant diabetes.
This study looks for factors that may help predict who will develop diabetes after a kidney transplant. It is for people who have not had diabetes before their transplant and are starting on tacrolimus and steroids.
This trial tests semaglutide, a medicine that helps lower blood sugar, in people who develop high blood sugar shortly after a kidney transplant. It may help control blood sugar without harming the transplanted kidney, while also checking safety in this specific group.
This trial is testing a medication called SGLT2i (a type of diabetes drug that also helps the heart and kidneys) in people who have received a heart transplant. It aims to see if this drug can improve health after transplant.
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
Hear when a new Sodium Glucose Co-Transporter 2 Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.